President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual ...

At UC, 70% of undergrads participate in research, creative projects or service learning. Three new programs bridge classroom ...

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing ...

Learn what the Nipah virus is, how it spreads, and why it has one of the highest fatality rates among infectious diseases.

Omeros Corporation (NASDAQ:OMER) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. [Operator Instructions] Please be ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...